Thiotepa: alkylating agent for chemotherapy

Tepadina (thiotepa) is a cytotoxic treatment for haematological disease and solid tumours. It is approved for use alongside other forms of chemotherapy in preparation for allogeneic or autologous haematopoietic progenitor cell transplantation.

Thiotepa acts as an alkylating agent. It has efficacy in a variety of malignancies, including lymphoma and myeloma, breast and ovarian cancer and tumours of the central nervous system and germ cells. Treatment must be supervised by a specialist.

View Tepadina drug record

Further information: Intrapharm

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Skin cancer warning for actinic keratosis treatment

Skin cancer warning for actinic keratosis treatment

Patients treated with ingenol mebutate (Picato) should...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Drug shortages - live tracker

Drug shortages - live tracker

Added: Accupro, Dermovate, Norinyl-1.
Use our...

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.